Forbius was acquired by Bristol Myers Squibb in August 2020, a company targeting hard-to-drug TFG-beta and EGFR pathways in Fibrosis and Cancer.
Forbius was acquired by Bristol Myers Squibb in August 2020, a company targeting hard-to-drug TFG-beta and EGFR pathways in Fibrosis and Cancer.